Sterling Capital Management’s Benitec Biopharma BNTC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.37K Buy
437
+28
+7% +$342 ﹤0.01% 2924
2026
Q2
$5.47K Buy
409
+283
+225% +$3.36K ﹤0.01% 2559
2026
Q1
$1.34K Buy
126
+29
+30% +$336 ﹤0.01% 3051
2025
Q4
$1.31K Buy
97
+61
+169% +$844 ﹤0.01% 3117
2025
Q3
$505 Buy
36
+1
+3% +$13 ﹤0.01% 3159
2025
Q2
$410 Buy
+35
New +$490 ﹤0.01% 3175

Other funds holding BNTC

Sterling Capital Management's BNTC Position: Q3 2026 in Review

Sterling Capital Management increased its Benitec Biopharma (BNTC) stake by 6.8% in Q3 2026, buying an estimated $342 and bringing the position to 437 shares worth $4.37K. The position accounts for ﹤0.01% of the portfolio, ranked #2924.

Sterling Capital Management first reported a position in BNTC in Q2 2025 and has held it in 6 quarters since. The position peaked at $5.47K in Q2 2026. 91 funds tracked by Wall St. Rank hold BNTC as of Q3 2026.

  • Sterling Capital Management held 437 shares of Benitec Biopharma worth $4.37K as of Q3 2026.
  • Sterling Capital Management bought 28 Benitec Biopharma shares in Q3 2026, an estimated $342.
  • Benitec Biopharma made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2924 holding.
  • Sterling Capital Management first reported a position in Benitec Biopharma in Q2 2025 and has held it in 6 quarters since.
  • Sterling Capital Management's Benitec Biopharma position peaked at $5.47K in Q2 2026.
  • 91 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.